Avience Biomedicals Lists at ₹395.20, Up 99.50%

Avience Biomedicals Ltd, incorporated in June 2024 as an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions focusing on biotechnology, genomics, and IVD industry with comprehensive product range including Rapid Test Kits for Dengue, Malaria, Syphilis, Biochemistry Analyzers and Reagents, Molecular Diagnostics including COVID-19 detection kits, Hematology Analyzers, and Medical Devices like oxygen concentrators catering to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas through B2B and B2G markets from manufacturing unit in Noida, Uttar Pradesh, made a stellar debut on NSE SME on Thursday, June 25, 2026. The Avience Biomedicals share price opened at ₹395.20 representing exceptional premium of 90.00% from issue price of ₹208.00, hit upper circuit at ₹414.95 (up 99.50%).

Avience Biomedicals Listing Details

Avience Biomedicals launched its fresh issue IPO at ₹196-208 per share with minimum investment of 1,200 shares costing ₹2,49,600 raising ₹30.24 crore including ₹8.52 crore from anchor investors. The IPO received exceptional response with subscription of 385.32 times - retail investors at 401.36 times, NII exceptionally strong at 597.23 times, QIB at 196.77 times, total applications of 1,92,952.

First-Day Trading Performance

Listing Price: Avience Biomedicals stock price opened at ₹395.20 representing exceptional premium of 90.00% from issue price, hit upper circuit at ₹414.95 (up 99.50%), with VWAP at ₹404.65. The stellar listing delivered near 100% returns for IPO investors with turnover of ₹23.53 crore, traded volume of 5.81 lakh shares, delivery of 100%, and market capitalisation of ₹227.60 crore against pre-IPO market cap of ₹114.09 crore.

Growth Drivers and Challenges

Growth Drivers:

Diversified Diagnostic Portfolio: Comprehensive product range spanning Rapid Test Kits, Biochemistry Analyzers, Molecular Diagnostics, Hematology Analyzers, and Medical Devices catering to pathology labs, hospitals, and research centers domestically and overseas.

Expansion into Medical Device Park: IPO proceeds of ₹14.05 crore dedicated to new manufacturing unit at YEIDA Medical Device Park, Gautam Buddha Nagar enhancing production capacity and regulatory compliance for scaling operations.

Strong Margins: EBITDA margin of 24.70%, PAT margin of 15.86% with ROE of 22.38% and ROCE of 16.99% reflecting high-value diagnostic products and efficient B2B/B2G distribution model.

Challenges:

Fully Priced Valuation: Issue appears fully priced at post-IPO P/E of 16.56x; analyst recommends only well-informed/cash surplus investors for long term despite strong listing gains.

Recent Incorporation: Company incorporated only in June 2024 with limited operating history; tiny paid-up equity capital indicates longer gestation period for mainboard migration.

Elevated Leverage: Debt/equity of 0.94 indicates moderate leverage; working capital funding of ₹8.25 crore from IPO proceeds to support inventory and receivables management.

Utilisation of IPO Proceeds

Capital Expenditure: ₹14.05 crore for setting up new manufacturing unit at Industrial Plot No. 70, Sector 28 in Medical Device Park under YEIDA, Gautam Buddha Nagar.

Working Capital: ₹8.25 crore for funding working capital requirements.

General Corporate Purposes: ₹3.97 crore.

Financial Performance

Revenue: ₹41.94 crore for 10 months ended January 2026 (91% of full FY25), ₹45.97 crore for FY25, growth from ₹24.37 crore in FY24.

Net Profit: ₹5.74 crore for 10 months FY26 (79% of full FY25), ₹7.23 crore in FY25 representing 238% growth from ₹2.14 crore in FY24, with post-IPO EPS of ₹12.56 and P/E of 16.56x. Investors tracking Avience Biomedicals share price should note exceptional 385x subscription with 1.93 lakh applications and near 100% listing gains.